UBS Group’s Palisade Bio PALI Stock Holding History

UBS Group’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.54M	Sell	737,307 -429,644	-37%	-$846K	﹤0.01%	5344
2026 Q1	$2.04M	Buy	1,166,951 +919,197	+371%	+$1.67M	﹤0.01%	4963
2025 Q4	$582K	Buy	247,754 +228,341	+1,176%	+$439K	﹤0.01%	5986
2025 Q3	$16.7K	Buy	19,413 +19,081	+5,747%	+$14.9K	﹤0.01%	8275
2025 Q2	$226	Sell	332 -37,751	-99%	-$27K	﹤0.01%	9914
2025 Q1	$25.9K	Buy	38,083 +29,109	+324%	+$34.4K	﹤0.01%	8044
2024 Q4	$14.8K	Buy	8,974 +8,943	+28,848%	+$23.5K	﹤0.01%	8070
2024 Q3	$110	Sell	31 -1,185	-97%	-$4.56K	﹤0.01%	9150
2024 Q2	$5.47K	Buy	1,216 +1,068	+722%	+$5.84K	﹤0.01%	7992
2024 Q1	$887	Sell	148 -20	-12%	-$140	﹤0.01%	8321
2023 Q4	$1.49K	Buy	168 +161	+2,300%	+$1.41K	﹤0.01%	8293
2023 Q3	$63	Hold	7	–	–	﹤0.01%	8974
2023 Q2	$184	Sell	7 -82	-92%	-$2.05K	﹤0.01%	8415
2023 Q1	$4.72K	Sell	89 -185	-68%	-$6.51K	﹤0.01%	8154
2022 Q4	$21.4K	Buy	274 +140	+104%	+$8.12K	﹤0.01%	7574
2022 Q3	$10K	Buy	134 +105	+362%	+$22.2K	﹤0.01%	8448
2022 Q2	$9K	Buy	29 +18	+164%	+$8.67K	﹤0.01%	8163
2022 Q1	$9K	Buy	11 +6	+120%	+$4.85K	﹤0.01%	8562
2021 Q4	$5K	Buy	5 +2	+67%	+$3.5K	﹤0.01%	9408
2021 Q3	$6K	Sell	3 -27	-90%	-$59.7K	﹤0.01%	8436
2021 Q2	$90K	Buy	30 +26	+650%	+$118K	﹤0.01%	5964
2021 Q1	$27K	Buy	4 +2	+100%	+$13.5K	﹤0.01%	7098
2020 Q4	$9K	Buy	+2	New	+$6K	﹤0.01%	7568
2020 Q3	–	Sell	-3	Closed	-$9.59K	–	8298
2020 Q2	$10K	Buy	3 +2	+200%	+$7.22K	﹤0.01%	7018
2020 Q1	$3K	Hold	1	–	–	﹤0.01%	7506
2019 Q4	$3K	Buy	+1	New	+$4.99K	﹤0.01%	7757
2019 Q3	–	Hold	0	–	–	–	8179
2019 Q2	–	Hold	0	–	–	–	7245
2019 Q1	–	Hold	0	–	–	–	7556
2018 Q4	–	Hold	0	–	–	–	7637
2018 Q3	–	Hold	0	–	–	–	7073
2018 Q2	–	Hold	0	–	–	–	7412
2018 Q1	–	Hold	0	–	–	–	6869
2017 Q4	–	Hold	0	–	–	–	7029
2017 Q3	–	Hold	0	–	–	–	7079
2017 Q2	–	Hold	0	–	–	–	6722
2017 Q1	–	Hold	0	–	–	–	5814
2016 Q4	–	Hold	0	–	–	–	7042
2016 Q3	–	Hold	0	–	–	–	7059
2016 Q2	–	Hold	0	–	–	–	7047
2016 Q1	–	Hold	0	–	–	–	5893
2015 Q4	–	Hold	0	–	–	–	6433
2015 Q3	–	Hold	0	–	–	–	6613
2015 Q2	–	Hold	0	–	–	–	6451
2015 Q1	–	Hold	0	–	–	–	6517
2014 Q4	–	Hold	0	–	–	–	7276

Other funds holding PALI

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

UBS Group's PALI Position: Q2 2026 in Review

UBS Group reduced its Palisade Bio (PALI) stake by 37% in Q2 2026, selling an estimated $846K and leaving 737,307 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #5344.

UBS Group first reported a position in PALI in Q4 2019 and has held it in 26 quarters since. The position peaked at $2.04M in Q1 2026. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

UBS Group held 737,307 shares of Palisade Bio worth $1.54M as of Q2 2026.
UBS Group sold 429,644 Palisade Bio shares in Q2 2026, an estimated $846K.
Palisade Bio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5344 holding.
UBS Group first reported a position in Palisade Bio in Q4 2019 and has held it in 26 quarters since.
UBS Group's Palisade Bio position peaked at $2.04M in Q1 2026.
124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.